These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9857998)

  • 1. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Kern JA; Herndon JE; Tatum A; Brisson ML; Memoli V; Sugarbaker D; Skarin AT; Kreisman H; Green MR
    Lung Cancer; 1998 Sep; 21(3):203-11. PubMed ID: 9857998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Tatum A; Herndon JE; Box J; Memoli V; Green MR; Kern JA
    Lung Cancer; 2001; 33(2-3):115-23. PubMed ID: 11551406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
    Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
    Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
    Linnoila RI; Piantadosi S; Ruckdeschel JC
    Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
    Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
    Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
    Petrović M; Ilić N; Baskić D
    Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
    Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
    Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
    Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
    Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
    Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
    Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy].
    Ohnoshi T; Ueoka H; Segawa Y; Kiura K; Tabata M; Shibayama T; Maeda T; Miyatake K; Takigawa N; Kimura I
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Feb; 30(2):262-9. PubMed ID: 1351108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
    Brooks KR; To K; Joshi MB; Conlon DH; Herndon JE; D'Amico TA; Harpole DH
    Ann Thorac Surg; 2003 Jul; 76(1):187-93; discussion 193. PubMed ID: 12842538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
    Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
    J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
    Petrović M; Baskić D; Banković D; Ilić N
    Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
    Kiriakogiani-Psaropoulou P; Malamou-Mitsi V; Martinopoulou U; Legaki S; Tamvakis N; Vrettou E; Fountzilas G; Skarlos D; Kosmidis P; Pavlidis N
    Lung Cancer; 1994 Dec; 11(5-6):353-64. PubMed ID: 7535640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer].
    Dabrowska M; Grubek-Jaworska H; Domagała-Kulawik J; Bartoszewicz Z; Kondracka A; Krenke R; Nejman P; Chazan R
    Pol Arch Med Wewn; 2004 Jun; 111(6):659-65. PubMed ID: 15508787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
    Shaw GL; Gazdar AF; Phelps R; Linnoila RI; Ihde DC; Johnson BE; Oie HK; Pass HI; Steinberg SM; Ghosh BC
    Cancer Res; 1993 Nov; 53(21):5181-7. PubMed ID: 8221655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.